Bank CEOs meet with Trump to discuss Fannie Mae and Freddie Mac - Bloomberg
Solid Biosciences (NASDAQ:SLDB) stock closed up 11% Tuesday following Cantor Fitzgerald’s reiteration of an Overweight rating and $16.00 price target on the company. According to InvestingPro data, analyst targets range from $10 to $20, suggesting significant upside potential. The stock has gained 81% over the past month as investors show interest in the company’s gene therapy approach, with year-to-date returns reaching 25.5%.
Cantor Fitzgerald met with Solid Biosciences management Tuesday in Boston to discuss early Phase 1/2 data from SGT-003, the company’s AAV-based gene therapy for Duchenne muscular dystrophy (DMD). The research firm described the preliminary results from three patients as "highly encouraging." InvestingPro analysis shows the company maintains a strong liquidity position with a current ratio of 10.89, though it’s currently experiencing rapid cash burn - a critical factor for biotechnology companies in development stages.
Solid Biosciences plans to discuss the regulatory pathway for SGT-003 with the FDA in the fourth quarter of 2025. The company has also indicated it will disclose additional patient data around year-end, with approximately 20 patients expected to receive treatment by that time.
The meeting included discussion of a second patient death from competitor Sarepta Therapeutics (NASDAQ:SRPT)’ AAV-based gene therapy ELEVIDYS, which was reportedly due to acute liver failure in a non-ambulatory patient. Solid Biosciences management expressed they were "heartbroken" by this news.
Tuesday’s stock performance suggests some investors recognize distinctions between the two companies’ therapeutic approaches rather than broadly categorizing them simply as "AAV-based gene therapies for DMD," according to Cantor Fitzgerald’s analysis of the market reaction.
In other recent news, Solid Biosciences has been the focus of several analyst updates and developments in its gene therapy programs. H.C. Wainwright reaffirmed its Buy rating and $20 price target on the company, highlighting the favorable safety profile of Solid Biosciences’ SGT-003 gene therapy compared to a competitor’s treatment for Duchenne muscular dystrophy (DMD). Truist Securities also maintained a Buy rating with a $16 price target, noting the progress in Solid Biosciences’ gene therapy programs for DMD, Friedreich’s ataxia, and catecholaminergic polymorphic ventricular tachycardia (CPVT), with significant updates expected in late 2025.
Piper Sandler adjusted its price target for Solid Biosciences to $17 while maintaining an Overweight rating, following the company’s first-quarter financial results and ongoing clinical trials. Jefferies lowered its price target to $15 but sustained a Buy rating, emphasizing the company’s adherence to program timelines and upcoming regulatory discussions. JMP Securities also kept a positive stance, reiterating a Market Outperform rating and a $15 price target, citing promising clinical data for SGT-003 and anticipated regulatory discussions.
Solid Biosciences is actively administering doses in the Phase 1/2 INSPIRE DUCHENNE trial, with data updates expected in the fourth quarter of 2025. The company is preparing to launch a Phase 1b study for Friedreich’s Ataxia and is on track to submit an IND application for CPVT. The company’s financial position remains strong, with over $300 million in cash expected to support key milestones. These developments indicate ongoing interest in Solid Biosciences’ gene therapy portfolio as the company navigates the complex gene therapy market.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.